Dharmacon™
Edit-R™ CRISPR-Cas9
Gene Engineering with
Lentiviral Cas9 and sgRNA
1 Introduction to the CRISPR-Cas9 system for gene engineering

CRISPR-Cas: an adaptive immunity defense mechanism in bacteria and archaea

The CRISPR (clustered regularly interspaced palindromic repeats)-Cas (CRISPR-associated protein) system is an adaptive bacterial and archaeal defense mechanism that serves to recognize and silence incoming foreign nucleic acids. Upon infection by bacteriophage or other foreign DNA elements, a host organism can incorporate short sequences from the invading genetic material, called protospacers, into a specific region of its genome (the CRISPR locus) between short palindromic DNA repeats of variable lengths. Multiple spacer-repeat units are clustered at the CRISPR locus to form the CRISPR array. The entire locus including the CRISPR array is transcribed by RNA polymerase into a primary transcript, the pre-CRISPR RNA (pre-crRNA), which is then processed into small, mature CRISPR RNAs (crRNAs) such that they include sequences complementary to the foreign, invading DNA. crRNAs guide a multifunctional protein or protein complex (the CRISPR-associated or Cas proteins) to cleave complementary target DNA that is adjacent to short sequences known as protospacer-adjacent motifs (PAMs). Thus, the organism acquires a way to protect itself from subsequent infection.1

Engineering a CRISPR-Cas9 platform for mammalian genome editing

Many bacterial and archaeal CRISPR-Cas systems have been identified with diverse sets of mechanisms, Cas proteins and multi-subunit complexes. In particular, the processes and key components of the Streptococcus pyogenes CRISPR-Cas9 system have been well studied and adapted for genome engineering in mammalian cells. In S. pyogenes, only three components are required for targeted DNA cleavage at specific target sites adjacent to a PAM:2 (1) The endonuclease Cas9, programmed by (2) a mature crRNA processed from transcription of the CRISPR locus/array which complexes with (3) another CRISPR locus-encoded RNA, the trans-activating CRISPR RNA (tracrRNA, Figure 1A).3 Alternatively, the crRNA can be fused to the tracrRNA creating a chimeric structure termed a single guide RNA (sgRNA, Figure 1B).2

Upon site-specific double-stranded DNA cleavage, a mammalian cell can repair such a break through either non-homologous end joining (NHEJ) or homology directed repair (HDR). NHEJ is often imperfect, resulting in small insertions and deletions (indels) that can cause nonsense mutations resulting in gene disruptions to produce gene knockouts.4,5 This endogenous DNA break repair process, coupled with the highly tractable S. pyogenes CRISPR-Cas9 system, allows for a readily engineered platform to permanently disrupt gene function.

Figure 1. Illustration of CRISPR-Cas9 system. Cas9 nuclease (light blue), programmed by the crRNA (green):tracrRNA (blue) complex (A) or the sgRNA (B), cutting both strands of genomic DNA 5’ of the PAM (red).
2 Gene editing using Edit-R Lentiviral Cas9 Nuclease with sgRNA particles

The Edit-R Lentiviral Gene Engineering platform includes two critical components based on the natural S. pyogenes system: a vector for Cas9 expression and a gene-specific vector for sgRNA expression designed to the target site of interest. To facilitate rapid generation of cell lines that constitutively express Cas9 nuclease and the sgRNA, the Cas9 and sgRNA vectors are packaged into lentiviral particles, purified and concentrated. Cas9-expressing cell lines can be easily generated with the Edit-R Lentiviral Cas9 Nuclease Expression particles and subsequent gene knockouts can be obtained by an additional transduction with sgRNA lentiviral particles or, alternatively, by transfection with synthetic crRNA:tracrRNA if the cells are amenable to transfection (see Edit-R™ CRISPR-Cas9 Gene Engineering with Lentiviral Cas9 and Synthetic crRNA:tracrRNA for more information and protocols). Figure 2 summarizes a general experimental workflow to generate stable cell lines expressing Cas9 nuclease followed by transduction with sgRNA lentiviral particles for phenotypic analysis of gene knockout.

![Figure 2. Gene knockout workflow using the Edit-R Lentiviral Cas9 Nuclease with sgRNA system. Gene editing with Edit-R Lentiviral Cas9 Nuclease and sgRNA can be done following a mixed cell populations approach (left side) typically for gene knockout screenings or on isolated clonal cells lines (right side) when a defined genotype is desired or required on each step for the phenotypic analyses.](image)
**Edit-R Lentiviral Cas9 Nuclease and sgRNA Expression vectors**

The Edit-R Lentiviral Cas9 Nuclease Expression vectors contain a human codon-optimized version of the *S. pyogenes* cas9 (csn1) gene and the blasticidin resistance marker (BlastR). Both are expressed as a bicistronic transcript with a 2A peptide sequence linker under the control of a single promoter (Figure 3). BlastR is placed upstream of the Cas9 coding region rather than on the 3' end so that no extra amino acids are added to the C-terminus, thus preserving the full Cas9 endonuclease activity. A brief description of the lentiviral vector elements are listed in Table 1. Multiple promoter options are available (Figure 3A) for selection of a Cas9 nuclease vector with the most active promoter for specific cells of interest.

In the Edit-R Lentiviral sgRNA vector backbone (Figure 3B), the gene-specific crRNA and the tracrRNA are expressed under the control of a human U6 promoter, while expression of the puromycin resistance marker (PuroR) is driven from the mouse CMV promoter and allows for rapid selection of cells with integrated sgRNA.

All Edit-R Lentiviral Cas9 Nuclease and sgRNA vectors are supplied as concentrated, purified lentiviral particles (≥ 1 × 10^8 TU/mL). The Edit-R Lentiviral Cas9 Nuclease Expression vectors are also supplied as dried down, endotoxin-free plasmid DNA, ready for lentiviral packaging.

### Table 1. Elements of the Edit-R Lentiviral Cas9 Nuclease Expression and sgRNA vectors.

<table>
<thead>
<tr>
<th>Vector Element</th>
<th>Utility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cas9</td>
<td>Human codon-optimized <em>S. pyogenes</em> Cas9 nuclease for cleavage of targeted DNA when programmed with a sgRNA</td>
</tr>
<tr>
<td>T2A</td>
<td>Self-cleaving peptide allows for simultaneous expression of blasticidin resistance and Cas9 protein from a single transcript</td>
</tr>
<tr>
<td>BlastR</td>
<td>Blasticidin resistance marker permits antibiotic selection of transduced mammalian cells</td>
</tr>
<tr>
<td>hCMV</td>
<td>Human cytomegalovirus immediate early promoter</td>
</tr>
<tr>
<td>mCMV</td>
<td>Mouse cytomegalovirus immediate early promoter</td>
</tr>
<tr>
<td>hEF1α</td>
<td>Human elongation factor 1 alpha promoter</td>
</tr>
<tr>
<td>mEF1α</td>
<td>Mouse elongation factor 1 alpha promoter</td>
</tr>
<tr>
<td>PGK</td>
<td>Mouse phosphoglycerate kinase promoter</td>
</tr>
<tr>
<td>CAG</td>
<td>Human cytomegalovirus, chicken β-actin hybrid promoter</td>
</tr>
<tr>
<td>U6</td>
<td>Human RNA polymerase III promoter U6</td>
</tr>
<tr>
<td>PuroR</td>
<td>Puromycin resistance marker permits antibiotic selection of transduced mammalian cells</td>
</tr>
<tr>
<td>5' LTR</td>
<td>5' Long Terminal Repeat necessary for lentiviral particle production and integration of the construct into the host cell genome</td>
</tr>
<tr>
<td>ψ</td>
<td>Psi packaging sequence allows lentiviral genome packaging using lentiviral packaging systems</td>
</tr>
<tr>
<td>RRE</td>
<td>Rev Response Element enhances titer by increasing packaging efficiency of full-length lentiviral genomes</td>
</tr>
<tr>
<td>WPRE</td>
<td>Woodchuck Hepatitis Post-transcriptional Regulatory Element enhances transgene expression in target cells</td>
</tr>
<tr>
<td>3' SIN LTR</td>
<td>3' Self-inactivating Long Terminal Repeat for generation of replication-incompetent lentiviral particles</td>
</tr>
<tr>
<td>SV40 pA</td>
<td>Simian virus 40 polyadenylation signal</td>
</tr>
<tr>
<td>pUC ori</td>
<td>pUC origin of replication</td>
</tr>
<tr>
<td>SV40 ori</td>
<td>Simian virus 40 origin of replication</td>
</tr>
<tr>
<td>AmpR</td>
<td>Ampicillin resistance gene for vector propagation in <em>E. coli</em> cultures</td>
</tr>
</tbody>
</table>

---

**Figure 3.** Schematic map of the Edit-R Lentiviral Cas9 Nuclease Expression (A) and sgRNA (B) vectors.
Each Edit-R Lentiviral sgRNA is specific to the gene or genomic site of choice. The crRNA region of the sgRNA is comprised of 19-20 nucleotides identical to the genomic DNA target site, or protospacer, followed by the non-variable sgRNA scaffold containing the tracrRNA sequence from *S. pyogenes*. The chosen genomic DNA target sequence must be immediately upstream of a PAM. The predominant *S. pyogenes* PAM nucleotide sequence is NGG. Pre-designed gene-specific sgRNAs can be ordered by searching for genes of interest on dharmacon.gelifesciences.com, or custom-designed using the Dharmacon CRISPR RNA Configurator.

### 3 Protocol for gene engineering using Edit-R Lentiviral Cas9 Nuclease and sgRNAs

The Edit-R Lentiviral Gene Engineering system utilizes Cas9 nuclease and the sgRNA in a two-step process. First, Edit-R Lentiviral Cas9 Nuclease Expression particles are utilized to generate cell lines stably expressing Cas9 nuclease. These cells can subsequently be transduced with Edit-R Lentiviral sgRNA particles to achieve efficient gene editing for phenotypic analyses in a population of cells or in isolated clonal cell lines.

**Edit-R CRISPR-Cas9 gene engineering materials required**

Edit-R Lentiviral Cas9 Nuclease Expression vectors are provided as concentrated, purified lentiviral particles for immediate transduction or as endotoxin-free plasmid DNA for direct transfection into a packaging cell line and production of your own lentiviral particles. Edit-R Lentiviral sgRNA particles are produced upon ordering and provided as concentrated, purified lentiviral particles for direct transduction.

- **Edit-R Lentiviral Cas9 Nuclease Expression particles with SMARTchoice promoter options:**
  - Edit-R™ Lentiviral hCMV-Blast-Cas9 Nuclease particles (Cat #VCAS10124)
  - Edit-R™ Lentiviral mCMV-Blast-Cas9 Nuclease particles (Cat #VCAS10125)
  - Edit-R™ Lentiviral hEF1α-Blast-Cas9 Nuclease particles (Cat #VCAS10126)
  - Edit-R™ Lentiviral mEF1α-Blast-Cas9 Nuclease particles (Cat #VCAS10127)
  - Edit-R™ Lentiviral PGK-Blast-Cas9 Nuclease particles (Cat #VCAS10128)
  - Edit-R™ Lentiviral CAG-Blast-Cas9 Nuclease particles (Cat #VCAS10129)

- **Edit-R™ Lentiviral Cas9 Nuclease Expression plasmids with SMARTchoice promoter options:**
  - Edit-R™ Lentiviral hCMV-Blast-Cas9 Nuclease plasmid (Cat #CAS10136)
  - Edit-R™ Lentiviral mCMV-Blast-Cas9 Nuclease plasmid (Cat #CAS10137)
  - Edit-R™ Lentiviral hEF1α-Blast-Cas9 Nuclease plasmid (Cat #CAS10138)
  - Edit-R™ Lentiviral mEF1α-Blast-Cas9 Nuclease plasmid (Cat #CAS10139)
  - Edit-R™ Lentiviral PGK-Blast-Cas9 Nuclease plasmid (Cat #CAS10140)
  - Edit-R™ Lentiviral CAG-Blast-Cas9 Nuclease plasmid (Cat #CAS10141)

- **Edit-R™ Lentiviral sgRNA particles:**
  - Custom sgRNA designed using the Dharmacon CRISPR RNA Configurator (Cat #VSG10154 and VSG10155) or
  - Pre-designed Edit-R sgRNA (Cat#VSGH10143 through VSGH10153)
**Additional materials required**

The following additional materials are required but not supplied:

- Multi-well tissue culture plates or tissue culture dishes
- Blasticidin S (Fisher Scientific, Cat #BP2647-25; InvivoGen, Cat #ant-bl-1)
- Puromycin (Fisher Scientific, Cat #BP2956-100; InvivoGen, Cat #ant-pr-1)
- Resazurin cell viability reagent or similar
- Assay(s) for detecting gene engineering events in a cell population
- Positive control sgRNA lentiviral particles:
  - Custom sgRNA designed using the Dharmacon CRISPR RNA Configurator (Cat #VSG10154 and VSG10155) or
  - Edit-R Human *PPIB* Lentiviral sgRNA Positive Control (Cat #VSGH10231)
  - Edit-R Human *DNMT3B* Lentiviral sgRNA Positive Control (Cat #VSGH10230)
  - Edit-R Mouse *Ppib* Lentiviral sgRNA Positive Control (Cat #VSGM10233)
  - Edit-R Mouse *Dnmt3b* Lentiviral sgRNA Positive Control (VSGM10232)
  - Edit-R Rat *Ppib* Lentiviral sgRNA Positive Control (VSGR10235)
  - Edit-R Rat *Dnmt3b* Lentiviral sgRNA Positive Control (VSGR10234)
- Edit-R Lentiviral sgRNA Non-targeting Controls:
  - sgRNA Non-targeting Control #1 (Cat #VSGC10215)
  - sgRNA Non-targeting Control #2 (Cat #VSGC10216)
  - sgRNA Non-targeting Control #3 (Cat #VSGC10217)
  - sgRNA Non-targeting Control #4 (Cat #VSGC10218)
  - sgRNA Non-targeting Control #5 (Cat #VSGC10219)
  - sgRNA Non-targeting Control #6 (Cat #VSGC10220)
  - sgRNA Non-targeting Control #7 (Cat #VSGC10221)
  - sgRNA Non-targeting Control #8 (Cat #VSGC10222)
  - sgRNA Non-targeting Control #9 (Cat #VSGC10223)
  - sgRNA Non-targeting Control #10 (Cat #VSGC10224)
- **Growth Medium**: antibiotic-free cell culture medium (with serum and/or supplements) recommended for maintenance of the cells of interest.
- **Transduction Medium**: the base cell culture medium containing lentiviral particles (with transduction additives and serum, if necessary).
- **Selection Medium**: Growth Medium supplemented with the appropriate concentration of blasticidin and/or puromycin.

**Generation of a stable cell line expressing Cas9 nuclease**

The protocol described here is designed for rapid generation of a cell population where most of the cells have a single copy of a lentiviral Cas9 nuclease proviral sequence in the genome.

Select the lentiviral Cas9 nuclease vector with the most active promoter in your cell line based on empirical testing or known promoter activity.
Blasticidin selection

The Edit-R Lentiviral Cas9 Nuclease Expression vectors confer resistance to blasticidin in transduced cells. Before transducing cells, determine the minimum concentration of blasticidin required to kill non-transduced cells between three and ten days by generating a blasticidin kill curve. The blasticidin concentration range for many mammalian cells is 2-15 μg/mL.

Transduction of cells with Edit-R Lentiviral Cas9 Nuclease Expression particles

The protocol below provides the basic steps for transduction of the lentiviral particles into U2OS cells (as an example) using serum-free medium in a 24-well plate. Permissivity to lentiviral delivery and optimal transduction conditions vary widely amongst cell types and must be determined empirically for each cell line of interest.

Day 1:
1. Plate 5 × 10⁴ cells per well in a 24-well plate using Growth Medium.
2. Incubate cells at 37 °C in a humidified CO₂ incubator overnight.

Day 2:
1. Prepare the Transduction Medium and equilibrate the medium to 37 °C.
2. Calculate the volume of lentiviral particles needed for transduction at MOI = 0.3.

The functional titer of Edit-R Lentiviral Cas9 Nuclease Expression particles (in HEK293T cells, as determined by qPCR) is reported on the Certificate of Analysis (C of A). We recommend an MOI of 0.3 (adjusted for relative transduction efficiency in your cell type) to ensure single integration of the lentiviral Cas9 nuclease. The relative transduction efficiency of your cell type will likely be lower than that of HEK293T cells. Thus, using an MOI of 0.3 based on the HEK293T titer reported on your C of A may be acceptable for generating a stable cell population with a single Cas9 integration.

The equation to calculate a volume of lentiviral stock for a given MOI is:

\[ V = \text{MOI} \times \text{CN} \div \text{VT} \times 1000 \]

Where:
- \( V \) = volume of lentiviral stock in µL
- \( \text{MOI} \) = desired multiplicity of infection
- \( \text{CN} \) = number of cells in the well at transduction
- \( \text{VT} \) = Viral titer in TU/mL (indicated in the Certificate of Analysis) and multiplied by 1000 to convert the volume from mL to µL

For example, for a desired MOI of 0.3 and:
- Cell density of 100 000 cells per well at time of transduction
- Lentiviral titer = 1 × 10⁸ TU/mL

Then,

\[ V = 0.3 \text{ TU/cell} \times 100 \,000 \text{ cells/well} \div 1 \times 10^8 \text{ TU/mL} \times 1000 = 0.3 \mu L \text{ of lentiviral stock/well.} \]
3. Thaw the Edit-R Lentiviral Cas9 Nuclease Expression particles on ice.

Lentiviral particles are shipped on dry ice as 25 μL aliquots and must be stored at -80 °C. Under these conditions, lentiviral particles are stable for at least 12 months. Repeated freeze-thaw cycles should be avoided, as this is expected to negatively affect titer. Once thawed, unused lentiviral particles should be kept on ice, divided into smaller aliquots (if necessary) and immediately returned to -80 °C.

4. Once thawed, gently mix and pipette the calculated volume of lentiviral particles into the Transduction Medium.

5. Remove the Growth Medium from the well and add 0.25 mL of the Transduction Medium containing the lentiviral particles (see Appendix for guidelines on other plate formats).

6. Incubate cells at 37 °C in a humidified CO₂ incubator for 4-6 hours.

7. Approximately 4-6 hours post-transduction, add an additional 0.75 mL of Growth Medium (with serum) and resume incubation at 37 °C in a humidified CO₂ incubator.

Days 3-15:

1. At 24-48 hours post-transduction, replace the medium with Selection Medium containing the appropriate amount of blasticidin.

2. Replace the Selection Medium every 3-4 days and monitor the presence of dead cells daily.

Blasticidin usually kills cells between three and ten days; slow growing cells may take longer. If the cells become confluent, split the cells into a larger dish to allow proper blasticidin selection (for example, split cells from 24-well to 6-well culture dishes).

3. Once the cells are growing normally in Selection Medium, expand the cells to freeze a sufficient number of aliquots for your experimental project.

Record the passage number and avoid working with stable cell populations at passage numbers exceeding 10 from frozen stock.

Utilize the mixed population of Cas9-expressing cell line obtained above for transduction with Edit-R Lentiviral sgRNA particles for phenotypic analysis by knockout of your gene of interest, or isolate clonal cell lines for downstream experiments using protocols appropriate for your cells of interest if clonal cell lines are desired.

Transduction of cells with Edit-R Lentiviral sgRNA particles

The protocol below is an example of Edit-R Lentiviral sgRNA Expression particles transduction at an MOI of 0.3 into adherent U2OS cells stably expressing Cas9 nuclease in 24-well plate format. Permissivity to lentiviral delivery and optimal transduction conditions vary widely amongst cell types and must be determined empirically for each cell line of interest.

Puromycin selection

The Edit-R Lentiviral sgRNA vector confers resistance to puromycin in transduced cells. Similar to blasticidin selection, before transducing cells, generate a puromycin kill curve to determine the minimum concentration of puromycin required to kill non-transduced cells between three and ten days. The puromycin concentration range for many mammalian cells is 1-10 μg/mL.
Day 1:
1. Plate $5 \times 10^4$ Cas9 Nuclease-expressing cells per well in a 24-well plate using Growth Medium.
2. Incubate cells at 37 °C in a humidified CO$_2$ incubator overnight.

Day 2:
1. Prepare the Transduction Medium and equilibrate the medium to 37 °C.
2. Calculate the volume of lentiviral particles needed for transduction at MOI = 0.3 (see Note above).
3. Thaw the Edit-R Lentiviral sgRNA particles on ice.
4. Once thawed, gently mix and pipette the calculated volume of lentiviral particles into the Transduction Medium.
5. Remove the Growth Medium from the well and add 0.25 mL of the Transduction Medium containing the lentiviral particles (see Appendix for guidelines on other plate formats).
6. Incubate cells at 37 °C in a humidified CO$_2$ incubator for 4-6 hours.
7. Approximately 4-6 hours post-transduction, add an additional 0.75 mL of Growth Medium (with serum) and resume incubation at 37 °C in a humidified CO$_2$ incubator.

Days 3-7:
1. At 24-48 hours post-transduction, replace the medium with Selection Medium containing the appropriate amount of puromycin.

Since the Cas9-expressing cells are resistant to blasticidin, addition of blasticidin to the Selection Medium containing puromycin is optional. If the cells become confluent, split the cells into a larger dish to allow proper antibiotic selection (for instance, split cells from 24-well to 6-well culture dishes).

2. Replace the Selection Medium every 2-3 days and monitor the presence of dead cells daily.
3. Once the cells are growing normally in Selection Medium, expand the cells to freeze a sufficient number of aliquots for your experimental project or proceed to isolation of clonal cell lines.
   a. Expansion of the puromycin/blasticidin-resistant cells at this stage will generate a mixed population of cells having a single integration of the sgRNA in their genomes, in addition to the single integration of Cas9 nuclease. This mixed population will carry a variety of insertions and deletions (indels) and can be used for phenotypic analysis of your gene knockout.
   b. If a defined mutation genotype is required, proceed to isolation of clonal cell lines using protocols appropriate for your cells of interest and determine the exact genotype by DNA sequencing.
4  Packaging Edit-R Lentiviral Cas9 Nuclease plasmids

Edit-R Lentiviral Cas9 Nuclease Expression plasmids are Tat-dependent and require a packaging system that expresses the tat gene. For packaging lentiviral constructs, we recommend the Dharmaco™ Trans-Lentiviral™ ORF Packaging System. For packaging protocols and additional information please consult the product manual.

5  Appendix

Gene editing assay recommendations

The most commonly used method for detection of insertions and deletions (indels) in a cell population is a mismatch detection assay such as SURVEYOR® Mutation Detection Kit (Integrated DNA Technologies) or T7 Endonuclease I (T7EI, NEB). When edited cells are expanded and clonal populations are obtained, the most commonly used method for confirming gene editing is Sanger sequencing.

Volume of Transduction Medium per surface area in culture dishes

Table 4. Suggested volumes of Transduction Medium per surface area per well of adherent cells.

<table>
<thead>
<tr>
<th>Tissue culture dish</th>
<th>Surface area per well (cm²)</th>
<th>Suggested total serum-free medium volume per well (mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>100 mm</td>
<td>56</td>
<td>5</td>
</tr>
<tr>
<td>6 well</td>
<td>9.4</td>
<td>1</td>
</tr>
<tr>
<td>12 well</td>
<td>3.8</td>
<td>0.5</td>
</tr>
<tr>
<td>24 well</td>
<td>1.9</td>
<td>0.25</td>
</tr>
<tr>
<td>96 well</td>
<td>0.3</td>
<td>0.05</td>
</tr>
</tbody>
</table>

Stability and storage

Lentiviral particles

Edit-R Lentiviral Cas9 Nuclease Expression and sgRNA particles are shipped on dry ice as 25 μL aliquots and must be stored at -80 °C. Under these conditions, lentiviral particles are stable for at least 12 months. Repeated freeze-thaw cycles should be avoided, as this is expected to negatively affect titer. Once thawed, unused lentiviral particles should be kept on ice, divided into smaller aliquots (if necessary) and immediately returned to -80 °C.

Plasmid DNA

Edit-R Lentiviral Cas9 Nuclease Expression plasmid DNA reagents are shipped as dried pellets at room temperature. Under these conditions, they are stable for at least four weeks. Upon receipt, plasmid DNA should be stored at -20 °C to -80 °C. Under these conditions, the reagents are stable for at least one year. Always dissolve plasmid in nuclease-free solution, such as nuclease-free 10 mM Tris pH 7.4.
6 Frequently asked questions

How do I choose between the various Edit-R Lentiviral Cas9 promoter options?
Choose the promoter option that has been demonstrated, either by your own experimental observations or through references in the published literature, to actively express a transgene in your cells of choice. For optimal experimental confidence (or if such information is not available), consider using multiple lentiviral promoter-Cas9 constructs or selecting the best promoter empirically using the Dharmacon SMARTchoice Promoter Selection Plate (Cat #SP-001000-01) (dharmacon.gelifesciences.com/shrna/smartchoice-shrna-promoter-selection-plate/).

What is the best way to confirm that my gene is knocked out?
Mismatch detection assays tell you that editing occurred in the cell population. Clonal cell isolation followed by DNA sequencing of the region of interest and determination of the protein functionality are necessary to confirm the gene knockout.

Can the Edit-R Lentiviral Cas9 system be used for gene knockout in non-mammalian organisms, such as flies or worms?
We have designed the Edit-R Cas9 plasmids and lentiviral particles for mammalian expression and thus have only tested in mammalian cells. We cannot predict the efficacy of using Edit-R Lentiviral Cas9 Nuclease and sgRNA Expression particles, nor can we troubleshoot experiments performed in non-mammalian systems.

Can I order the Edit-R Lentiviral sgRNA Expression vector as plasmid DNA?
No. Our Edit-R Lentiviral sgRNA Expression vectors are made to each specific customer order and are sold exclusively as lentiviral particles.

Can I co-transduce the Edit-R Lentiviral Cas9 Nuclease Expression and my sgRNA particles in my cell lines to generate my gene knockout faster?
Although this is not the recommended protocol, transduction of both the Edit-R Lentiviral Cas9 Nuclease Expression and the sgRNA particles can be performed at the same time. If co-transduction is necessary, it is recommended to extend the dual antibiotic selection to the longest selection time period previously determined for the individual antibiotics in your cells. We cannot predict the outcome, nor troubleshoot any issues, resulting from co-transduction of Cas9 and sgRNA lentiviral particles.
7 References


8 Lentiviral particle product safety level information

This Lentiviral Particle Product Safety Level Information constitutes Product Documentation according to clause 1 of the Product Terms and Conditions. It is applicable to all Dhharmacon lentiviral particle products.

Any investigator who purchases Dhharmacon lentiviral particle products is responsible for consulting with their institution’s health and biosafety personnel for specific guidelines on the handling of lentiviral vector particles. Furthermore, each investigator is fully responsible for obtaining the required permissions for research use and the acceptance of replication-incompetent SIN lentiviral vectors and replication-defective lentiviral particles into their local jurisdiction and institution.

The Products are solely for internal research use (as set forth in the Product Terms and Conditions) in laboratories where the containment measures stated below and in applicable laws and regulations are met. Products may not be used for diagnostic, therapeutic or other commercial purposes and may not to be administered to humans for any purpose or to animals for therapeutic purposes. The Products are replication-incompetent, self-inactivating (SIN) and non-pathogenic (do not cause infectious human disease).
For questions concerning the design or production of the products, please contact our technical support team.

GE Healthcare Dharmacon, Inc.
2650 Crescent Drive
Lafayette, CO 80026 USA
Tel. +1 800 235 9880; +1 303 604 9499
Fax: +1 800 292 6088; +1 303 604 9680
Email: TS.Dharmacon@ge.com (North America) or TS.Dharmacon.eu@ge.com (Europe)

**In the US:**

For US guidance on containment for lentiviral vectors, please refer to:

1. The Recombinant DNA Advisory Committee (RAC) guidelines for research with lentiviral vectors [http://osp.od.nih.gov/office-biotechnology-activities/biosafety/biosafety-guidance];
2. The U.S. Department of Health and Human Services Centers for Disease Control and Prevention and National Institutes of Health, Biosafety in Microbiological and Biomedical Laboratories (BMBL);

**In the EU:**

For the EU directives, please consult the following:


**In Germany:**

Required Containment Measures: The containment requirements as stated in the German Genetic Safety Ordinance (Gentechnik-Sicherheitsverordnung) of Safety Level 2* or higher have been assigned to the handling of the above-mentioned lentiviral vector particles. Please note a higher Security Level might be required if the lentiviral vector particles are used for genetic engineering operations with other products which require a higher Security Level.

*Safety Level 2: activities of low risk for human health and the environment by the state of scientific knowledge (Stand der Wissenschaft).

For the German regulations, please consult the following:

1. German Genetic Engineering Act (Gentechnikgesetz - GenTG); and
2. Genetic Engineering Safety Ordinance (Gentechnik-Sicherheitsverordnung - GenTSV).
9 Limited use licenses

The Products, use and applications, are covered by pending and issued patents. The following Label Licenses govern all use of the Products. It is each Purchaser’s responsibility to determine if patent or other intellectual property rights held by third parties may restrict the use of Products for a particular application.

The Broad Institute Inc. and Massachusetts Institute of Technology

Limited License to Use. The purchase of this product from Dharmacon or its Affiliates conveys to the final purchaser ("Limited Licensee") a non-transferable right to use the CRISPR Products solely for research conducted by Limited Licensee in accordance with all of the following requirements: (i) The Limited Licensee shall not sell or otherwise transfer products (including without limitation any material that contains a CRISPR Product in whole or part) to any other person or entity, or use CRISPR Products to perform services for the benefit of any other person or entity, provided however, that a Limited Licensee that is an academic, nonprofit, or government entity or person may perform core facility services for its academic and teaching purposes; (ii) the Limited Licensee shall use only the amount of the CRISPR Products purchased from Dharmacon, and components of such CRISPR Products, and shall use any materials made using the CRISPR Products by such Limited Licensee, only for its internal research as a research tool for research purposes, and not for any commercial purposes, (iii) the Limited Licensee shall use CRISPR Products in compliance with all applicable laws and regulations, including without limitation applicable human health and animal welfare laws and regulations, (iv) Broad, MIT and Harvard shall provide no warranties of any kind to the Limited Licensee (statutory or implied concerning certain patent rights owned by Broad, MIT and Harvard or the CRISPR Products), including without limitation, as to product quality, condition, description, merchantability, fitness for a particular purpose, noninfringement of intellectual property rights or the absence of latent or other defects, and all such warranties are hereby expressly disclaimed, (v) Broad, MIT and Harvard shall also expressly disclaim any warranty regarding results obtained through the use of the CRISPR Products, including without limitation any claim of inaccurate, invalid or incomplete results, (vi) Broad, MIT and Harvard, and their directors, trustees, officers, employees, agents, faculty, affiliated investigators, and students, shall have no liability to the Limited Licensee, including, without limitation, for any loss of use or profits, business interruption or any consequential, incidental, special or other indirect damages of any kind, regardless of how caused and regardless of whether an action in contract, tort, strict product liability or otherwise, (vii) the Limited Licensee shall indemnify, defend and hold harmless MIT, Harvard and Broad against any liability, damage, loss, or expense (including without limitation reasonable attorneys’ fees and expenses) incurred by or imposed upon MIT, Harvard and Broad in connection with any claims, suits, investigations, actions, demands or judgments arising out of or related to the exercise of any rights granted to the Limited Licensee under the Limited License or any breach of the Limited License by such Limited Licensee; provided, however, that the foregoing shall not apply to a Limited Licensee that is an academic, non-profit, or government entity or person, and such Limited Licensee instead agrees that it, and not MIT, Harvard and Broad, shall be responsible for any liability, damage, loss or expense arising out of or related to the exercise of any rights granted to the Limited Licensee under the Limited License or any breach of the Limited License by the Limited Licensee, and (viii) the CRISPR Product and its use may be the subject of one or more issued patents and/or pending patent applications owned by Broad, MIT and Harvard and the purchase of the CRISPR Product does not convey a license under any claims in the foregoing patents or patent applications directed to the CRISPR Product or use, production or commercialization thereof.
Salk Institute Restricted Use Label License

THE SALK INSTITUTE

PURCHASER NOTIFICATION

1. The Nature of the LICENSEE License: Licensee has a license to sell the Product containing WPRE, under the terms described below. Any use of WPRE outside of Licensee's Product or the Product's intended use, requires a license as detailed below. Before using the Product containing WPRE, please read the following license agreement. If you do not agree to be bound by its terms, contact Licensee within 10 days for authorization to return the unused Product containing WPRE and to receive a full credit.

2. Patents: The WPRE technology is covered by patents issued to The Salk Institute for Biological Studies.

3. Individual License: The WPRE technology is covered by patents issued to The Salk Institute for Biological Studies.

4. Agreement: Licensee grants you a non-exclusive license to use the enclosed Product containing WPRE in its entirety for its intended use. The Product containing WPRE is being transferred to you in furtherance of, and reliance on, such license. Any use of WPRE outside of Licensee's Product or the Product's intended use, requires a license from the Salk Institute for Biological Studies.

5. Termination of License: This license agreement is effective until terminated. You may terminate it at any time by destroying all Products containing WPRE in your control. It will also terminate automatically if you fail to comply with the terms and conditions of the license agreement. You shall, upon termination of the license agreement, destroy all Products containing WPRE in your control, and so notify Licensee in writing. This License shall be governed in its interpretation and enforcement by the laws of the State of California.

6. Contact for WPRE Licensing: The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037

Attn.: Office of Technology Management
Phone: 858 453 4100 extension 1703
Fax: 858 546 8093

Sigma-Aldrich Restricted Use Label License

For Research Use Only - Not for any Clinical, Therapeutic or Diagnostic use in Humans.

These Products may be subject to the following patents (issued or pending):

**BENITEC TECHNOLOGY LICENSED PATENTS**

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Patent No.</th>
<th>Application No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Graham/Rice</td>
<td>Control of Gene Express</td>
<td>ZA 2000/4507*</td>
<td>HK 01105904.3*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU2001/100608*</td>
<td>HU P0101225*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SG15542*</td>
<td>IN 200000 169/DEL*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6,573,099*</td>
<td>JP P2000-537990</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GB 2353282*</td>
<td>KR 710144/2000*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 743316*</td>
<td>M9000631*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 506648*</td>
<td>PL P343064*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 10/346853*</td>
<td>SK PV 1372-2000*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU PQ900997/0*</td>
<td>AU 35647/DZ*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR P9903867/0*</td>
<td>NZ 5259641*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2327326*</td>
<td>SG020205122-5*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CB 9804255-2*</td>
<td>US 09646807*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CZ P82000-3346*</td>
<td>PPO40298*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 999100399.9*</td>
<td>AU PP24999/98*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US10/646,070</td>
<td>US 10/821,710*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 10/759,841*</td>
<td>US 10/821,726*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 040150419.9*</td>
<td>AU 2005209648*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU2005211538</td>
<td></td>
</tr>
<tr>
<td>Graham/Rice/M/R</td>
<td>Genetic Silencing</td>
<td>WO 017057994*</td>
<td>SG 91678*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GB 237722</td>
<td>ZA 200207428*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU PQ85833</td>
<td>AU2003240375*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU PR2700</td>
<td></td>
</tr>
<tr>
<td>Graham, et al.</td>
<td>Double-Stranded Nucleic Acid</td>
<td>AU 2003906281*</td>
<td>AU 200490227*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2003906281*</td>
<td>PCT/AU04/000759</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 10/861,191*</td>
<td></td>
</tr>
</tbody>
</table>

*Indicates a “Co-Owned Patents” are jointly owned by Benitec and CSIRO.
## OXFORD TECHNOLOGY

<table>
<thead>
<tr>
<th>PCT Application (filing date)</th>
<th>Priority Application(s) (filing date)</th>
<th>National Application</th>
<th>Issued Patents</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>JP 3-514518</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2,104,396</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 84302/91</td>
<td>0572401</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>3547129</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>6656470</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2,104,396</td>
</tr>
<tr>
<td>WO 92/05266</td>
<td>US 07/1,70,515 (21 March 1988)</td>
<td>US Continuation 08/462,492</td>
<td>5,716,832</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US Continuation 10/205,179</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 88424/91</td>
<td>665176</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU Divisional 47984/96</td>
<td>690427</td>
</tr>
<tr>
<td>WO 98/17815</td>
<td></td>
<td>EP 97/909436.4</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP Divisional 00202432.1</td>
<td>6,312,682</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 09/224,014</td>
<td>6,669,936</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US Divisional 09/91,5169</td>
<td>7,198,784</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US CIP 10/661,781</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>US Continuation 11/646,041</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 10-519086</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 47122/97</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 97198767.X NZ 334860</td>
<td></td>
</tr>
<tr>
<td>WO 98/17816</td>
<td></td>
<td>EP 97/990437.2</td>
<td>2,97198767.X</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 09/264,011</td>
<td>334860</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 10-519087</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 47123/97</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 97198883.8</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 334522</td>
<td>7787801</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2,97198883.8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>334522</td>
</tr>
<tr>
<td>WO 98/18934</td>
<td></td>
<td>US Continuation 11/155,043</td>
<td>7056,699</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US Continuation 11/726,679</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 10-520197</td>
<td></td>
</tr>
</tbody>
</table>

This Product and its use are the subject of one or more of the following patents: 6,682,907; 7,981,671; 8,093,042; 8,367,068; 8,450,087; 8,460,678; 8,512,994 and/or other foreign patents or pending applications licensed to GE Healthcare Dharmacon Inc. The purchase of this Product conveys to the Buyer the non-transferable right to use the purchased amount of the Product and components of the Product in research conducted by the Buyer (whether the Buyer is an academic or for-profit entity). The Buyer cannot sell or otherwise transfer this Product, its components or materials made using this Product or its components to a third party or otherwise use this Product or its components or materials made using this Product or its components for any commercial purposes. If the Buyer is not willing to accept the limitations of this limited use statement, Dharmacon is willing to accept return of the Product with a full refund. For information on purchasing a license to the DNA-Flap technology for purposes other than research, contact the Transfer of Technology Office, Institut Pasteur, 28 rue du Docteur Roux, 75 724 Paris Cedex 15 (www.pasteur.fr).
Tranzyme Restricted Use Label License

Portions of this Product are covered by several patent applications owned by, or licensed to, Tranzyme, Inc. The purchase of this Product conveys to the buyer the limited, non-exclusive, nontransferable right (without the right to resell, repackage, or further sublicense) under these patent rights to perform the viral infection methods using the lentiviral vectors claimed in those patent applications for research purposes solely in conjunction with this Product. No other license is granted to the buyer whether expressly, by implication, by estoppel or otherwise. In particular, the purchase of this Product does not include nor carry any right or license to use, develop, or otherwise exploit this Product commercially, and no rights are conveyed to the buyer to use the Product or components of the Product for any other purposes, including without limitation, provision of services to a third party, generation of commercial databases, or clinical diagnostics or therapeutics.

This Product is sold pursuant to a license from Tranzyme, Inc., and Tranzyme, Inc. reserves all other rights under these patent rights. For information on purchasing a license to the patent rights for uses other than in conjunction with this Product or to use this Product for purposes other than research, please contact the licensing officer at 919 313 4760.